Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells | BMC Cancer | Full Text

Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells | BMC Cancer | Full Text

Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells

Hepatocellular carcinoma (HCC) is the leading cause of cancer-related deaths worldwide. The only drug currently approved for clinical use in the treatment of advanced HCC is sorafenib. However, many patients w...

Authors:Hanhee Jo, Yusun Park, Taehun Kim, Jisu Kim, Jong Sook Lee, Seon Yoo Kim, Jee-in Chung, Hae yong Ko, Jae-Chul Pyun, Kyung Sik Kim, Misu Lee and Mijin Yun

Citation:BMC Cancer 2020 20:332

Content type:Research article

Published on: 19 April 2020

• ViewFull Text
 
• ViewPDF